Member Info for sadoldgit

I agree with you whole heartedly there. I feel much better today as after a 13 hr drive back from Thurso to home after 1 days work and when I finally arrive home I find I have left my one and only house key at Thurso. Using the window at the moment untill I get loch changed later. Yes, had a little top up too yesterday and if price slides down ( which I do not think will be much) will buy some more.
Back to Tims presentation. Very poor and the uumming and erring does not depict confidence in the individual. I sincerely hope that he makes a better presentation this month and comes across with a more confident, goal orientated individual with a planned schedule for the TYK2 inhibitors as opposed to an easily excitable, nervous like individual that looks as if he cannot wait to get back to his train set.
The products we have are top notch, at the same time it is no good having the best product in the world but not having a front man capable of selling it to a prospective buyer.
He is scientist after all, not a salesman and very modest man indeed, I remember him saying ' what we are very good at is making chemicals'. Yes Tim you are and no question of that. But please lad just brush up on your presentation skills.

Thanks for the 11.41post

Even if Tim would announce that they are in discussions with regards to possible licensing or partnership agreement or similar whilst witholding who they are in discussions with would help calm investors frustrations at the moment. He did get his fingers burnt in 2012 with the 'transformation deal' which never materialised. he is not likely to make that mistake again.

These discussions I presume would be informal. Therefore no need to inform shareholders or interested parties. There still are loose ends that need tidying up ie Lupus report, suitability as a Covid treatment and the patent (1802) before any serious negotiations can take place.
Interested parties will not pay top dollar with missing or incomplete factual information, due to doubt/lack of confidence.
After satisfactory (on both sides} informal discussions, should it venture into formal discussions ie contract conditions and a formal offer made whether acceptable or not would have to be notified to shareholders.
It is not a serious problem it just takes time. Sareum will and are running lowish on funds. They have raised over a million pounds in placings and have circa 900k in the bank so all is well from that side.
The only question I would have for Tim is would he be carrying out research work into Tyk 2 as a potential treatment for Covid-19 if no receipt of a grant?

Has Tim received the Lupus report yet?

Good post UTAH and it keeps progress on TYK2. Still areas need tidying up with regards to patent and feedback from Dod. More good done than harm.

In many cases for a grant to be funded you have to be able to provide that you have finances available apart from the grant to support your work. No money in the bank to finance, no bloody grant.

Around 8 million buys than sells. Market sentiment! Blue next week me thinks.

Just to add krone. It all depends on the conditions that a license for any reason is granted. Sareum have the final say. It also depends on the amount of input/contribution a partner can afford to put in. The more they put in, the more they can expect to get out. All down to negotiation of course.

All we can do at the moment is summise. Sareum are watertight !

In my opinion Krone, if there is a grant and a partnership is formed then this would in its simplest form would be an agreement for the development and treatment of Covid-19. I dont think the partner would be granted a license for anything else non corona virus related.

However, the treatment may be suitable to use for similar, but non Covid 19 related ailments. Furthermore, the drug if suitable for the treatment of Covid-19 may well be suitable for any similar SARS virus.
I am sure these areas of permitted usage will have been discussed and negotiated already, if not already discussed are and will be in progress.
It should have no effect on 1801 for anything else. 1801 can be continued with a protected patent and wholly owned by Sareum except with a license for covid related diseases.
If we have interested parties ( as TM say we do) and a party does choose or has already chosen to undergo a partnership ( subject to grant of course), things will hot up very quickly and so will the SP.
With regards to a timeline it did not take long for the unknown Chinese pharma to take up the license opportunity. For peanuts? Maybe. The important part here is there was never any hint of such negotiations taking place.
Sareum to some may appear slow in progress. However, I as well as many others believe they have taken their time to get things right. Show me a compound they have which has performed poorly. They have placed their expertise on getting their compounds spot on.

As a question here:- What comes first the grant or the partner? Since the grant will not be enough to complete on its own that only leads to one conclusion. Negotiations are already taking place, loose ends need tidying up, the grant granted and a lovely little RNS indicating the state of play.
A friend over in Manila facing heavy lockdown as province just recorded 1000 new cases yesterday. There have been riots recently and people shot and killed. No mention of this on main stream media of course. Covid-19 is not going soon and neither are its mutations.
It takes time to get things right as opposed to throw any old 1st generation inhibitor, with ( in some cases severe side affects ) with the ultimate objective of making big bucks on nigh obsolete old treatments. Remdisivir has not been granted a license for general use by the NDA only for emergency use only.
I digress, in my opinion we will know by the end of June close to 5 weeks. That is my best guestimate. I can not see any reason as to why it should take longer.

The priority is to produce a first class product that will cure people and limit the death toll. If any of the newbies or even those that claim to have been here years know of any potentially better compound /treatment available then please let us know who and what they are.
Regards all.

I would think judging by the automated trades they are doing just that. Am reasonably new to here with a holding of only 27k .

You sound so knowledgeable. Is there a deal being negotiated at the moment? How long does the negotiations in these deals take? Last deal announced March 26th with China pharma.

I also like the 'been rumoured for weeks' been rumours here for weeks!

Up and coming presentations for Sierra Oncology. CHK! very conspicuous by its absence, a big push on Momelotinib, Is it feasible that Sierra Oncology want to gain funds to take CHK1 for themselves. Was NG in the pockets of Gilead?

https://www.prnewswire.com/news-releases/sierra-oncology-announces-presentations-at-upcoming-investor-conferences-301065651.html

Remdisivir is being tralled over here now for Covid patients in the NHS. In my opinion I would say there have been serious discussions with ICR and Sierra Oncology which has expediated the resignation of No Good. If and when it goes back to ICR that is a futher multi million pound loss for Sierra Oncology. I am surprised he has lasted that long.
Best to resign as publicity not good for company id fired, maintains an impression of integrity on both sides.

It will most likely be shown as a delayed trade.

Ahfam, Criteria for fast tracking a drug. This is NDA but will be very similar to European requirements :-

If there are existing therapies, a fast track eligible drug must show some advantage over available treatment, such as:
Showing superior effectiveness
Avoiding serious side effects of an available treatment
Improving the diagnosis of a serious disease where early diagnosis results in an improved outcome
Decreasing a clinically significant toxicity of an available treatment
Addressing an expected public health need.

Addressing an unexpected health need would appear to fit the bill.

Very promising paragraph on the sareum website:-

' Whilst developing SDC-1801, we have produced compelling cellular and in-vivo data in models of autoimmune disease to demonstrate the beneficial effects of SDC-1801 in modulating the key cytokines involved in the cytokine storm phase of Covid-19. Details can be made available to potential funding, collaboration and/or licensing partners on request.'

Sareum must be working away in the background as I believe this is the first mention of this. Presumably this info would be made available to those involved in grant application. Note the use of the term ' demonstrate the beneficial effects'. There is no ambiguity here at all.

I have a feeling we have a good week coming!

Worth reading especially towards the end. The 50k is of not much use to SAR and would have been applied for in April. It is the bigger packages of R&D at the bottom which is more of an interest, Dated 26/05/20

https://www.cambridgenetwork.co.uk/news/£40m-grant-funding-confirmed-business-projects-tackling-post-covid-19-global-impact